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Osteoarthritis (OA) has long been considered a “wear and tear” disease leading to loss of cartilage. OA
used to be considered the sole consequence of any process leading to increased pressure on one
particular joint or fragility of cartilage matrix. Progress in molecular biology in the 1990s has profoundly
modiﬁed this paradigm. The discovery that many soluble mediators such as cytokines or prostaglandins
can increase the production of matrix metalloproteinases by chondrocytes led to the ﬁrst steps of an
“inﬂammatory” theory. However, it took a decade before synovitis was accepted as a critical feature of
OA, and some studies are now opening the way to consider the condition a driver of the OA process.
Recent experimental data have shown that subchondral bone may have a substantial role in the OA
process, as a mechanical damper, as well as a source of inﬂammatory mediators implicated in the OA
pain process and in the degradation of the deep layer of cartilage. Thus, initially considered cartilage
driven, OA is a much more complex disease with inﬂammatory mediators released by cartilage, bone and
synovium. Low-grade inﬂammation induced by the metabolic syndrome, innate immunity and inﬂam-
maging are some of the more recent arguments in favor of the inﬂammatory theory of OA and high-
lighted in this review.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) has long been considered a “wear and tear”
disease leading to loss of cartilage. OA used to be considered the
sole consequence of any process leading to increased pressure on
one particular joint (e.g., overload on weight-bearing joints,
anatomical joint incongruency) or fragility of cartilage matrix
(genetic alterations of matrix components). This paradigm was
mainly based on the observation that chondrocytes, the only cell
type present in cartilage, have very low metabolism activity with
no ability to repair cartilage. Moreover, unlike all other tissues,
articular cartilage, once damaged, cannot respond by a usual
inﬂammatory response because it is non-vascularized and non-
innervated.
Progress in molecular biology in the 1990s has profoundly
modiﬁed this paradigm. The discovery that many soluble mediators
such as cytokines or prostaglandins can increase the production of
matrix metalloproteinases (MMPs) by chondrocytes led to the ﬁrst
steps of an “inﬂammatory” theory. However, it took a decade before
synovitis was accepted as a critical feature of OA, and some studies
are now opening the way to consider the condition a driver of theF. Berenbaum, Department of
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s Research Society International. POA process. Recent experimental data have shown that sub-
chondral bone may have a substantial role in the OA process, as
a mechanical damper, as well as, as a source of inﬂammatory
mediators implicated in the OA pain process and in the degradation
of the deep layer of cartilage. Thus, initially considered cartilage
driven, OA is a much more complex disease with inﬂammatory
mediators released by cartilage, bone and synovium1e3 (Fig. 1).
Interestingly, the source and type of inﬂammatory mediators may
differ by OA phenotype4.
Synovitis (local inﬂammation) in OA
Joint swelling is one clinical feature of OA attributed to inﬂam-
mation and reﬂecting the presence of synovitis due to thickening of
the synovium or to effusion. When patients experience OA ﬂares
(night pain, morning stiffness), they usually exhibit in parallel joint
effusion, as is seen in classical inﬂammatory arthropathies such as
rheumatoid arthritis (RA)5. Pannus-like synovitismayoccur, although
much more rarely than in RA6. Gadolinium-enhanced MRI and
ultrasonography are reliable, valid tools for showing OA synovitis7.
Many studies suggest that the presence of synovitis seen by
arthroscopy, magnetic resonance imaging (MRI) or ultrasonography
may be a surrogate marker of severity and associated with increased
riskof radiographic evidenceofdiseaseprogression8,9. Systemichigh-
sensitivity C-reactive protein levels reﬂect synovial inﬂammation inublished by Elsevier Ltd. All rights reserved.
Fig. 1. Systemic effects and potential consequences of OA-derived inﬂammatory mediators. A proposed novel paradigm for the role of low-grade inﬂammation in OA. Low-grade
inﬂammation is characterized by the release of inﬂammatory mediators into the blood during MetS (obesity, insulin resistance, lipid abnormalities, hypertension) or aging
(secretory senescence, see text). These inﬂammatory mediators are deleterious for joint tissues, thus initiating and/or perpetuating the OA process. Once activated, OA joint cells in
turn release inﬂammatory mediators into the joint cavity and eventually into the blood. The mediators amplify the low-grade inﬂammation, which may induce or accelerate other
chronic diseases affected by systemic low-grade inﬂammation.
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synovial inﬂammation frequently occurs in traumaticmeniscal injury
and is associated with increased pain and dysfunction12.
Why the synovium becomes inﬂamed in OA remains contro-
versial13. The most accepted hypothesis is that, once degraded,
cartilage fragments fall into the joint and contact the synovium.
Considered foreign bodies, synovial cells react by producing
inﬂammatory mediators, found in synovial ﬂuid. These mediators
can activate chondrocytes present in the superﬁcial layer of carti-
lage, which leads to metalloproteinase synthesis and, eventually,
increase cartilage degradation. The mediators can also induce
synovial angiogenesis and increase the synthesis of inﬂammatory
cytokines and MMPs by synovial cells themselves (vicious circle).
Thus, OA synovitis perpetuates the cartilage degradation.
More recently, another theory involves synovial tissue as
a primary trigger of the OA process. Indeed, many cell types usually
present in immunological processes have been described in OA, as
bystanders and as actors14. Depleting synovial macrophages with
clodronate liposome before inducing a collagenase-induced insta-
bility model of OA in mice prevented the generation of MMP-
induced neoepitopes into cartilage15,16, which indicates an impor-
tant role for synovial macrophages in MMP-mediated cartilage
damage. Moreover, osteophyte formation was decreased, which
suggests that these cells are pivotal for this feature16. Synovial
Inﬂammation may drive synovial angiogenesis, linked to OA pain,
through macrophage activation17,18. Molecular markers for
dendritic cells were detected in the synovium in a post-traumatic
rabbit OA model. Interestingly, large numbers of such cells were
observed in the early stages after surgery, which suggested their
participation in the early stages of OA19. Suurmond et al. showed anincreased expression of interleukin 17 (IL-17) in OA synovial tissue,
synovial mast cells being the main IL-17-positive cells20.
Innate immunity as a trigger of local inﬂammation in OA
The innate immune system, also known as non-speciﬁc immune
system, comprises the cells and mechanisms that defend the host
from infection by other organisms in a non-speciﬁc manner. This
system is triggered after the binding of pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular
patterns (DAMPs) on pattern-recognition receptors (PRRs)21,22. Thus,
these responses have been studied as predominant features in
multiple non-infectious diseases with tissue injury and/or defective
repair. PRRs include membrane-associated PRRs (Toll-like receptors
[TLRs], the basic signaling receptors of the innate immune system),
cytoplasmic PRRs (nucleotide-binding oligomerization domains
[NODs], NALPs, RNA helicases) and secreted PRRs (complement
receptors, collectins). PAMPs include bacterial and viral ligands and
also extracellular matrix molecules. PAMPs are recognized by TLRs
and other PRRs. A pioneer study showed that TLRs are increased in
level in OA cartilage lesions23. TLR-2 and TLR-4 ligands such as low-
molecular-weight hyaluronic acid, ﬁbronectin, tenascin-C and alar-
mins (S100 proteins, high-mobility group protein B1 [HMGB1]) have
been found in OA synovial ﬂuid24e26. These factors can induce
catabolic responses in chondrocytes and/or inﬂammatory responses
in synoviocytes. For example, S100A8 and S100A9 proteins are
involved in synovial activation and cartilage destruction, and high
levels may predict joint destruction in OA27. These results are
corroborated by a proteomic analysis revealing that proteins fromOA
synovial ﬂuid can induce macrophage production of inﬂammatory
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that these events may occur early in the disease, so innate immunity
may be a driver of the OA process. Synovial ﬂuid from patients with
early OA cartilage damage showed increased ﬁbroblast-like syno-
viocyte responses to TLR-2 and TLR-4 ligands28. Increased levels of
interleukin-15 (IL-15) protein are found in the synovial ﬂuid of early
knee OA patients when compared to end-stage OA, and numbers of
CD8 cells within the synovialmembrane is correlatedwithMMP-129.
Another group of proteins involved in innate immunity has
recently been highlighted in the context of OA. With proteomic and
transcriptomic analyses of synovial ﬂuids and synovial membranes
from subjects with OA, Qiang et al. found that the expression and
activation of complement is abnormally high in human OA joints30.
Moreover, with experimental OA-induced in mice genetically
deﬁcient in different complement factors or by using speciﬁc
pharmacological inhibitors, the authors showed that dysregulation
of complement in synovial joints may have a key role in OA
pathogenesis.
Innate immunity responses may be triggered by crystals31.
Calcium pyrophosphate dihydrate and basic calcium phosphate
crystals are common in OA joint ﬂuids and tissues32. These crystals,
along with uric acid, can interact with the NALP-3 inﬂammasome,
an intracellular protein complex involved in IL-1b and IL-18 acti-
vation by cleaving pro-caspase-1 to caspase-133,34. These processes
have been well described in gout, but whether they occur in OA
remains debatable35.
Low-grade systemic inﬂammation in OA
Local production of inﬂammatory mediators are well known to
contribute to cartilage degradation and synovial cell activation, but
additional data may link these events to a more systemic pathway.
In other words, inﬂammatory events occurring within joint tissues
could be reﬂected outside the joint in plasma and peripheral blood
leukocytes (PBLs) of patients with OA. Levels of several inﬂamma-
tory mediators are higher in OA than healthy sera27,36,37. A
remarkable study assessed gene expression proﬁles in PBLs from
patients with OA and found a subset with activated PBLs38. Inter-
estingly, cluster analysis revealed two distinct subgroups: one with
increased level of IL-1b and one with normal expression. Patients
with the inﬂammatory “IL-1b signature” had higher pain scores and
decreased function and were at higher risk of radiographic
progression of OA.
The risk of hand OA is increased two-fold in obese patients39.
This increased risk cannot be explained by the mechanical effect of
overload but can certainly be explained by systemic factors released
mainly by abdominal adipose tissue and able to reach and then
activate joint cells40. These systemic factors, called adipokines, have
been extensively studied in OA. Among them, leptin, adiponectin,
resistin and visfatin/NAMPT have pro- and/or anti-inﬂammatory
properties in OA41e43. Interestingly, recent epidemiological and
clinical data have highlighted that a metabolic syndrome (MetS)
rather than obesity itself has the greatest impact on the initiation
and severity of OA44e46. In that context, it is noteworthy that there is
an independent association between carotid intima medial thick-
ness with the prevalence of knee OA (OR 1.7, 1.1e2.7), and carotid
plaque with distal interphalangeal OA (OR 1.4, 1.2e1.7)47. The
reasons why there is such a link between atherosclerosis and OA
remains elusive. One hypothesis relies on the inﬂammatory theory
of atherosclerosis. Several lines of evidence support the hypothesis
that oxidized lipids, including oxidized low-density lipoprotein (ox-
LDL), are the most likely triggering factors for cytokine produc-
tion48. All these data give strength to the “adipokines theory,”
because the concentration of plasma adipokines is known to be
associated with MetS49. Not unsurprisingly, a study showed anassociation of serum adipokine concentration and OA severity50,51.
Moreover, systemic adipokines were found associated with local
synovial tissue inﬂammation52. Recently, the infrapatellar fat pad,
an adipose tissue localized in the knee, was found to be a potential
source of adipokines such as IL-653,54. Whether these discoveries
would lead to “anti-adipokine” therapies remain hypothetical since
these molecules participate into many other physiological
processes. However, some data coming from pre-clinical studies
could open opportunities. An inhibitor of visfatin/nicotinamide
phosphoribosyltransferase (NAMPT), FK866, has recently demon-
strated anti-arthritic properties55. Another result supporting the
role of adipokines relates on the clinical efﬁcacy of a dramatic
weight loss by bariatric surgery of obese patients on knee OA that
parallels a decrease of low-grade inﬂammatory systemic markers56.
A unique study could change the paradigm of the role of
inﬂammation in OA in the near future. Kyrkanides et al. induced OA
in mice genetically at risk of Alzheimer disease57. OA exacerbated
and accelerated the development of neuroinﬂammation as
assessed by glial cell activation and quantiﬁcation of inﬂammation-
related mRNAs, as well as Ab pathology, assessed by the number
and size of amyloid plaques. A likely scenario is that circulating
cytokines contribute to brain inﬂammation and may exacerbate it
in the context of Alzheimer disease.
Thus, OA could be initiated and/or aggravated by the presence of
a systemic low-grade inﬂammation but this study supports also the
hypothesis that OA could be at the initiation of distant age-related
diseases via a joint release of inﬂammatory mediators into the
blood stream (Fig. 1). Further experimental and epidemiological
studies are needed to conﬁrm this provocative hypothesis.
Aging, inﬂammation and OA
Inﬂammation is triggered by external mediators such as cyto-
kines and proteases, as well as internal cellular mechanisms
leading to increased production of inﬂammatory mediators and
lack of elimination of oxidated proteins. These proteins will in turn
increase the concentration of reactive oxygen species (ROS) in cells,
further adding to the oxidative damage triggering the inﬂamma-
tion58. Interestingly, oxidative stress can promote cell senescence,
and in particular chondrocyte senescence59.
Although OA is a prototypic age-related disease, the speciﬁc
mechanisms underlying the process remain largely unknown. At
the cellular level, senescence can be divided into two main cate-
gories: replicative and secretory. Many human cells in culture have
a limited proliferative capacity. After a period of vigorous prolifer-
ation, the rate of cell division declines (replicative senescence).
However, other cell types like chondrocytes have a lower capacity
to divide, which leaves little room for replicative senescence. But
these cells have high capacity to synthesize soluble mediators. So,
secretory senescence should be predominant with aging. This
condition has been called the senescence-associated secretory
phenotype (SASP) that includes several inﬂammatory and prode-
gradative mediators driven by oxidative stress60. Interestingly, the
SASP is primarily a delayed response to (epi)genomic damage61.
Indeed, IL-1b-stimulated MMP-13 chondrocyte production
increases with age, suggesting that aging chondrocytes acquire
a SASP62.
Another theory relating inﬂammation, aging and OA is based on
the recent discovery that advanced glycation endproducts (AGEs),
produced by a non-enzymatic process in aging tissues, weaken
cartilage by modifying its mechanical properties. They can trigger
chondrocyte activation by binding to speciﬁc receptors present at
the surface of the chondrocytes, called RAGE (receptors for AGE).
This process can lead to an overproduction of proinﬂammatory
cytokines and MMPs63e65.
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To understand why the incidence of OA increases greatly after
menopause, somegroupshave investigatedestrogenregulation. The
estrogen receptor is present in chondrocytes, subchondral osteo-
blasts and synoviocytes66. Its activation by estrogen derivatives has
led to controversial results, depending on their concentration.
However, the overall effect predominantly leads to inhibition of the
expression and secretion of proinﬂammatory cytokines such as IL-1
into the joint67. Moreover, decreased ovarian function is accompa-
nied by a spontaneous increase in level of proinﬂammatory cyto-
kines in plasma68, which may participate in the low-grade
inﬂammation mentioned here previously. However, this sugges-
tion is speculative because the literature is poor on the topic.
A direct link between mechanics and inﬂammation:
mechanoreceptor signaling
The controversy about the origin of the OA process, mechanics
or inﬂammation, should be ended soon thanks to recent discoveries
in mechanosignaling. Any abnormal mechanical stress applied on
a joint (stretch, compression, shear stress, hydrostatic pressure) can
be converted into activated intracellular signals in joint cells by
mechanoreceptors present at the surface of joint cells (ion chan-
nels, integrins)69. These signals may eventually lead to the over-
expression of inﬂammatory soluble mediators such as
prostaglandins, chemokines and cytokines when a certain
threshold is reached70. This is the case for chondrocytes and for
subchondral bone cells present in subchondral bone71e74. Intra-
cellularly, the conversion of a mechanical signal to the synthesis of
inﬂammatory mediators is mediated by the activation of inducible
signaling pathways. Among them, NF-kB andMAPK pathways seem
predominant75.
Therapeutical consequences
It is noteworthy that despite strong experimental studies
described in this review and showing a central role of inﬂammation
in OA, the anti-cytokine approach has not yet proven signiﬁcative
improvement in OA symptoms and structure modiﬁcation. Pilot
and controlled studies using anti-IL-1 and anti-TNF molecules have
not been convincing yet76,77. However, a very recent open-labeled
trial with etanercept is encouraging78. These disappointing
results may be due to the heterogeneity of the OA patients included
in these trials, including phenotypes that may have different
pathophysiology (Fig. 2).MetS OA Ageing OAPost-trauma OA
Systemic release of inflammatory mediators
Low- grade
Inflammation
Secretory
Inflammatory
phenotype
OSTEOARTHRITIS
Local
Inflammation
(synovitis,
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Fig. 2. An hypothesis for the role of inﬂammation in the pathogenesis of OA according
to the phenotype. For each phenotype, the main pathway leading to the release of
inﬂammatory mediators by the joint is highlighted. However, some pathways are
shared between phenotypes.Conclusions
The literature is rich in data suggesting that inﬂammatory
mediators playa pivotal role in the initiation andperpetuationof the
OA process. The source of such mediators would be local from joint
cells and systemic fromother tissues such as adipose tissue released
in blood ﬂow and then reaching the joint via the subchondral bone
vasculature. These mediators then have a deleterious effect on
cartilage, bone and synovium. By extrapolation, more recent data
suggest that locally producedmediators may have an impact on the
initiation and perpetuation of other age-related and metabolic
diseases. Deciphering these inﬂammatory pathways is critical for
the discovery of disease-modifying OA drugs in the future.
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